Pantoprazol G.L (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazol G.L, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults.

GNH USA supplies Pantoprazol G.L as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol G.L is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates mucosal healing and reduces further erosion. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours. - Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and prevents recurrence.

Pantoprazol G.L may cause a range of adverse reactions. The profile includes both frequent, mild events and rare, potentially serious conditions.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea: occasional mild upset. - Abdominal pain: cramp‑like discomfort. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis requiring medical attention. - Acute interstitial nephritis: kidney inflammation presenting with reduced urine output. - Severe hypersensitivity: rash, angio‑edema or anaphylaxis. - Osteoporosis‑related fractures: increased risk with long‑term use. - Vitamin B12 deficiency: may develop after prolonged therapy.

When prescribing Pantoprazol G.L, consider the following safety measures: - Assess renal function: dose adjustment may be required in severe impairment. - Evaluate hepatic status: use with caution in moderate to severe liver disease. - Review long‑term use: monitor for bone density loss and vitamin B12 levels. - Pregnancy and lactation: prescribe only if the potential benefit outweighs risk. - Drug‑interaction review: check concomitant medications for known interactions. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Pantoprazol G.L can affect the pharmacokinetics of several co‑administered drugs. Interaction monitoring is advised as follows:

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption and efficacy. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (clopidogrel): possible reduction in antiplatelet effect. - Warfarin: potential alteration of INR values. - Methotrexate: increased systemic exposure, especially at high doses. - Digoxin: modest increase in serum levels. - Oral contraceptives: possible decrease in hormonal efficacy.